

1. *Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction*
Stone, G.W., et al.
N Engl J Med, 2009. **360**(19): p. 1946-59.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19420364

2. *Long-term safety and efficacy of drug-eluting versus bare-metal stents in Sweden*
James, S.K., et al.
N Engl J Med, 2009. **360**(19): p. 1933-45.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19420363

3. *Impact of drug-eluting versus bare-metal stents on mortality in patients with anemia*
Shishehbor, M.H., et al.
JACC Cardiovasc Interv, 2009. **2**(4): p. 329-36.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19463445

4. *Baseline fractional flow reserve and stent diameter predict optimal post-stent fractional flow reserve and major adverse cardiac events after bare-metal stent deployment*
Samady, H., et al.
JACC Cardiovasc Interv, 2009. **2**(4): p. 357-63.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19463450

5. *Impact of sex on 3-year outcome after percutaneous coronary intervention using bare-metal and drug-eluting stents in previously untreated coronary artery disease: insights from the RESEARCH (Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated at Rotterdam Cardiology Hospital) Registries*
Onuma, Y., et al.
JACC Cardiovasc Interv, 2009. **2**(7): p. 603-10.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19628181

6. *The risk of stent thrombosis in patients with acute coronary syndromes treated with bare-metal and drug-eluting stents*
Kukreja, N., et al.
JACC Cardiovasc Interv, 2009. **2**(6): p. 534-41.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19539258

7. *Comparison of drug-eluting and bare-metal stents for stable coronary artery disease*

Horst, B., et al.

JACC Cardiovasc Interv, 2009. **2**(4): p. 321-8.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19463444

8. *The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) Randomized Trial*

Di Lorenzo, E., et al.

JACC Cardiovasc Interv, 2009. **2**(6): p. 515-23.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19539255

9. *Impact of target lesion and nontarget lesion cardiac events on 5-year clinical outcomes after sirolimus-eluting or bare-metal stenting*

Chacko, R., et al.

JACC Cardiovasc Interv, 2009. **2**(6): p. 498-503.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19539252

10. *3-year comparison of drug-eluting versus bare-metal stents*

Applegate, R.J., et al.

JACC Cardiovasc Interv, 2009. **2**(3): p. 231-9.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19463431

11. *Safety and effectiveness of drug-eluting and bare-metal stents for patients with off- and on-label indications*

Ko, D.T., et al.

J Am Coll Cardiol, 2009. **53**(19): p. 1773-82.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19422984

12. *2-year clinical outcomes after implantation of sirolimus-eluting, paclitaxel-eluting, and bare-metal coronary stents: results from the WDHR (Western Denmark Heart Registry)*

Kaltoft, A., et al.

J Am Coll Cardiol, 2009. **53**(8): p. 658-64.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19232897

13. *Outcome of drug-eluting versus bare-metal stenting used according to on- and off-label criteria*

Carlsson, J., et al.

J Am Coll Cardiol, 2009. **53**(16): p. 1389-98.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19371822

14. *5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents*

Caixeta, A., et al.

J Am Coll Cardiol, 2009. **54**(10): p. 894-902.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19712798

15. *A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial*

Brilakis, E.S., et al.

J Am Coll Cardiol, 2009. **53**(11): p. 919-28.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19281920

16. *Sirolimus-eluting stents, bare metal stents or coronary artery bypass grafting for patients with multivessel disease including involvement of the proximal left anterior descending artery: analysis of the Arterial Revascularization Therapies study part 2 (ARTS-II)*

Kukreja, N., et al.

Heart, 2009. **95**(13): p. 1061-6.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19304671

17. *Temporal changes in coronary revascularization procedures, outcomes, and costs in the bare-metal stent and drug-eluting stent eras: results from the US Medicare program*

Ryan, J., et al.

Circulation, 2009. **119**(7): p. 952-61.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19204307

18. *Volumetric intravascular ultrasound analysis of Paclitaxel-eluting and bare metal stents in acute myocardial infarction: the harmonizing outcomes with revascularization and stents in acute myocardial infarction intravascular ultrasound substudy*

Maehara, A., et al.

Circulation, 2009. **120**(19): p. 1875-82.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19858413

19. *Comparison of bare metal stenting and percutaneous pulmonary valve implantation for treatment of right ventricular outflow tract obstruction: use of an x-ray/magnetic resonance hybrid laboratory for acute physiological assessment*

Lurz, P., et al.

Circulation, 2009. **119**(23): p. 2995-3001.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19487596

20. *Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies*

Kirtane, A.J., et al.

Circulation, 2009. **119**(25): p. 3198-206.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19528338

21. *Long-term safety and effectiveness of unprotected left main coronary stenting with drug-eluting stents compared with bare-metal stents*

Kim, Y.H., et al.

Circulation, 2009. **120**(5): p. 400-7.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19620506

22. *Long-Term outcome of drug-eluting stents compared with bare metal stents in ST-segment elevation myocardial infarction: results of the paclitaxel- or sirolimus-eluting stent versus bare metal stent in Primary Angioplasty (PASEO) Randomized Trial*

Di Lorenzo, E., et al.

Circulation, 2009. **120**(11): p. 964-72.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19720939

23. *Early stent thrombosis in patients with acute coronary syndromes treated with drug-eluting and bare metal stents: the Acute Catheterization and Urgent Intervention Triage Strategy trial*

Aoki, J., et al.

Circulation, 2009. **119**(5): p. 687-98.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19171852

24. *Extended follow-up by serial angioscopic observation for bare-metal stents in native coronary arteries: from healing response to atherosclerotic transformation of neointima*

Yokoyama, S., et al.

Circ Cardiovasc Interv, 2009. **2**(3): p. 205-12.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20031717

25. *A randomized controlled trial of angiography versus intravascular ultrasound-directed bare-metal coronary stent placement (the AVID Trial)*

Russo, R.J., et al.

Circ Cardiovasc Interv, 2009. **2**(2): p. 113-23.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20031704

26. *Effect of length and diameter of drug-eluting stents versus bare-metal stents on late outcomes*

Applegate, R.J., et al.

Circ Cardiovasc Interv, 2009. **2**(1): p. 35-42.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20031691

27. *Clinical outcomes of drug-eluting versus bare-metal in-stent restenosis*

Singh, I.M., et al.

Catheter Cardiovasc Interv, 2009.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19937786

28. *Comparing long-term outcomes between drug-eluting and bare-metal stents in*

the treatment of cardiac allograft vasculopathy

Nfor, T., et al.

Catheter Cardiovasc Interv, 2009. **74**(4): p. 543-9.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19405161

29. *Angiographic and clinical outcomes of drug-eluting versus bare metal stent deployment in the Occluded Artery Trial*

Dzavik, V., et al.

Catheter Cardiovasc Interv, 2009. **73**(6): p. 771-9.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19309733

30. *Long-term clinical benefit of drug-eluting stents over bare-metal stents in diabetic patients with de novo left main coronary artery disease: results from a real-world multicenter registry*

Capodanno, D., et al.

Catheter Cardiovasc Interv, 2009. **73**(3): p. 310-6.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19214964

31. *Comparison of neointimal hyperplasia with drug-eluting stents versus bare metal stents in patients undergoing intracoronary bone-marrow mononuclear cell transplantation following acute myocardial infarction*

Villa, A., et al.

Am J Cardiol, 2009. **103**(12): p. 1651-6.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19539071

32. *Timing of noncardiac surgery after coronary artery stenting with bare metal or drug-eluting stents*

van Kuijk, J.P., et al.

Am J Cardiol, 2009. **104**(9): p. 1229-34.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19840567

33. *Comparison of drug-eluting stents and bare-metal stents for the treatment of unprotected left main coronary artery disease in acute coronary syndromes*

Tamburino, C., et al.

Am J Cardiol, 2009. **103**(2): p. 187-93.

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation>

n&list_uids=19121434

34. *Outcome differences with the use of drug-eluting stents for the treatment of in-stent restenosis of bare-metal stents versus drug-eluting stents*
Steinberg, D.H., et al.
Am J Cardiol, 2009. **103**(4): p. 491-5.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19195508

35. *Comparison of outcomes using bare metal versus drug-eluting stents in coronary artery disease patients with and without human immunodeficiency virus infection*
Ren, X., et al.
Am J Cardiol, 2009. **104**(2): p. 216-22.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19576350

36. *Major adverse cardiac events at follow-up after bare-metal stenting versus drug-eluting stenting in ST-elevated myocardial infarction*
Pierre-Louis, B., et al.
Am J Cardiol, 2009. **103**(12): p. 1672-4.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19539074

37. *Comparison of six-month outcomes for primary percutaneous revascularization for acute myocardial infarction with drug-eluting versus bare metal stents (from the APEX-AMI study)*
Patel, M.R., et al.
Am J Cardiol, 2009. **103**(2): p. 181-6.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19121433

38. *Clinical outcomes after sirolimus-eluting, paclitaxel-eluting, and bare metal stents (from the first phase of the prospective multicenter German DES.DE Registry)*
Nienaber, C.A., et al.
Am J Cardiol, 2009. **104**(10): p. 1362-9.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19892051

39. *Frequency of coronary artery bypass grafting following implantation of a paclitaxel-eluting or a bare-metal stent into a single coronary artery*

Martin, J.L., et al.

Am J Cardiol, 2009. **103**(1): p. 11-6.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19101222

40. *An integrated TAXUS IV, V, and VI intravascular ultrasound analysis of the predictors of edge restenosis after bare metal or paclitaxel-eluting stents*

Liu, J., et al.

Am J Cardiol, 2009. **103**(4): p. 501-6.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19195510

41. *Three-year survival following multivessel percutaneous coronary intervention with bare-metal or drug-eluting stents in unselected patients*

Kukreja, N., et al.

Am J Cardiol, 2009. **103**(2): p. 203-11.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19121437

42. *Impact of different re-stenting strategies on expansion of a drug-eluting stent implanted to treat bare-metal stent restenosis*

Kalinczuk, L., et al.

Am J Cardiol, 2009. **104**(4): p. 531-7.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19660607

43. *Comparison of long-term outcomes of bare metal or drug-eluting stent implantation in standard versus off-label coronary narrowings*

Harjai, K.J., et al.

Am J Cardiol, 2009. **103**(11): p. 1537-45.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19463512

44. *Comparison of long-term efficacy of the paclitaxel-eluting stent versus the bare-metal stent for treatment of unprotected left main coronary artery disease*

Han, Y., et al.

Am J Cardiol, 2009. **103**(2): p. 194-8.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19121435

45. *Histopathology of clinical coronary restenosis in drug-eluting versus bare metal stents*
Chieffo, A., et al.
Am J Cardiol, 2009. **104**(12): p. 1660-7.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19962471
46. *Comparison of outcomes of drug-eluting stents versus bare-metal stents in nonostial proximal left anterior descending coronary arteries*
Bonello, L., et al.
Am J Cardiol, 2009. **103**(4): p. 496-500.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19195509
47. *Drug-eluting versus bare-metal stents for treating saphenous vein grafts*
Shishehbor, M.H., et al.
Am Heart J, 2009. **158**(4): p. 637-43.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19781425
48. *Three-year clinical outcome after primary stenting of totally occluded native coronary arteries: a randomized comparison of bare-metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions (Primary Stenting of Totally Occluded Native Coronary Arteries [PRISON] II study)*
Rahel, B.M., et al.
Am Heart J, 2009. **157**(1): p. 149-55.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19081412
49. *Stent thrombosis up to 3 years after stenting for ST-segment elevation myocardial infarction versus for stable angina--comparison of the effects of drug-eluting versus bare-metal stents*
Leibundgut, G., et al.
Am Heart J, 2009. **158**(2): p. 271-6.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19619705
50. *Patterns of use of thienopyridine therapy after percutaneous coronary interventions with drug-eluting stents and bare-metal stents*
Ko, D.T., et al.

Am Heart J, 2009. **158**(4): p. 592-598 e1.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19781419

51. *Benefits of drug-eluting stents as compared to bare metal stent in ST-segment elevation myocardial infarction: four year results of the PaclitAxel or Sirolimus-Eluting stent vs bare metal stent in primary angioplasty (PASEO) randomized trial*

Di Lorenzo, E., et al.

Am Heart J, 2009. **158**(4): p. e43-50.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19781402

52. *Analysis of the long-term effects of drug-eluting stents on coronary arterial wall morphology as assessed by virtual histology intravascular ultrasound*

Kubo, T., et al.

Am Heart J, 2010. **159**(2): p. 271-7.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20152226